
Labcorp is pleased to announce our new portfolio of breakthrough biomarker tests for preeclampsia risk assessment and clinical management across all pregnancy trimesters, including a first trimester screening test and late trimester evaluation test.
Our testing options deliver on growing patient demand as 91% of pregnant and recently delivered individuals want early predictive testing for preeclampsia and 88% would be more inclined to follow medication guidance if found to be high-risk.1
As the only lab to offer a first trimester preeclampsia screening test, and the first to launch an FDA-cleared test for late trimester preeclampsia risk evaluation, Labcorp can support you in driving positive outcomes.
Ready to learn more? Watch our video from the 2024 Annual Meeting of the Society for Maternal-Fetal Medicine or click here.
Reference:
1. Cowan A, Haverty C, MacDonald R, Khodursky A. Impact of early preeclampsia prediction on medication adherence and behavior change: a survey of pregnant and recently‑delivered individuals. BMC Pregnancy and Childbirth. 2024;24(1):196 https://doi.org/10.1186/s12884-024-06397-z